Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.
The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.
This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.
Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.
Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.
To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.
India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.
Credit: Canva, CDSCO
The Central Drugs Standard Control Organisation (CDSCO) has now launched a nationwide crackdown on unapproved Fixed Dose Combination (FDCs) after 90 combination medicines that were being sold without mandatory central approval were busted last week.
CDSCO, India's apex drug regulatory body in the country, made the shocking discovery after scrutinizing drug samples uploaded on the SUGAM portal, the government’s online system for drug testing data.
Several of these samples were found to fall under the ‘new drug’ category but lacked approval from the central authority. As a result, the CDSCO wrote a letter to all states and union territory drug controllers, asking them to investigate manufacturers and marketers of these FDCs.
The letter reads: "The SUGAM lab testing data for the year 2025, a large number of drug samples (FDCs) are detected as unapproved and fall under the category of 'New Drug'. No new drug shall be manufactured for sale unless it is approved by the Licensing Authority 'as defined in Rule 3 of New Drugs and Clinical Trial Rules, 2019, Further, as per Rule 80 of New Drugs & Clinical Trial Rules 2019, a person who intends to manufacture new drug in the form of API or Pharmaceuticals formulation, as the case may be, for sale or distribution, shall make an application for grant of permission to the Central Licensing Authority in Form CT-21 along with a fee as specified in Sixth Schedule."
"The presence of unapproved drugs in the supply chain is a matter of serious concern, posing potential risks to public health and safety. It also indicates non- compliance with the provisions of the Drugs and Cosmetics Act, 1940, and rules made thereunder.
"Accordingly, please initiate appropriate investigation and regulatory action against the concerned manufacturers, marketers, and other stakeholders, as deemed fit. Kindly ensure strict monitoring and enforcement to prevent manufacture, sale, and distribution of such unapproved drugs," the letter states, on appropriate action against the sale and distribution of unapproved drugs.
FDCs are drugs that contain two or more active ingredients in a single formulation. The CDSCO has asked states to investigate and submit reports on the action taken at the earliest.
Cough And Cold Medicines
Cough and cold combination medicines have formed the single largest group. At least 14 to 16 entries show combination of ingredients found in everyday pharmacy shelves: dextromethorphan, ambroxol, guaiphenesin, chlorpheniramine, phenylephrine, terbutaline, and menthol in various permutations.
Several of these are sold as flavoured syrups for children. Budesonide-levosalbutamol inhalation suspension that is used for asthma and chronic obstructive pulmonary disease, too features in the list.
Nutritional Supplements
The next group is of the vitamins, minerals and other nutritional supplement which has roughly 18 to 20 entries. They include:
This group has accounted for at least 10 entries, which include antifungal creams that could lead to potential misuse and skin damage when sold without prescriptions.
Anti-Diabetic Medicines
This has accounted for six entries, and the combination includes:
Under India's New Drugs and Clinical Trial Rules of 2019, any FDC is treated as a new drug and must have the central government's approval before it could be manufactured and sold. The regulator's letter noted that there were presence of unapproved drugs in the supply chain that could pose risks to public health. This also amounts to a violation of the Drugs and Cosmetics Act, 1940.
“The presence of unapproved drugs in the supply chain is a matter of serious concern, posing potential risks to public health and safety. It also indicates non- compliance with the provisions of the Drugs and Cosmetics Act, 1940, and Rules made thereunder," it said.
DCGI urged states and UTs "to examine the unapproved FDCs in generic name as mentioned in the attached annexure". This is done to check whether any approval has been granted by the local office. "Accordingly, please initiate appropriate investigation and regulatory action against the concerned manufacturers, marketers, and other stakeholders, as deemed fit. Kindly ensure strict monitoring and enforcement to prevent the manufacture, sale, and distribution of such unapproved drugs," the letter noted.
Credit: Canva
Breakbone Fever, also known as dengue, is a mosquito-borne disease that is once again on the rise, with the U.S. Centers for Disease Control and Prevention issuing a travel alert across 17 Countries.
The federal agency flagged 'Level 1' risk for breakbone fever, calling for practicing usual precautions. It stated a higher-than-expected number of cases and urged people planning to travel to countries with an uptick in cases to be aware of the risk.
The CDC alert issued on March 23 identified 17 countries reporting an increased number of cases of dengue. These include: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, Vietnam, and the United States territories of American Samoa, Puerto Rico, and the US Virgin Islands, where local transmission is already common.
In 2026, the US reported a total of 496 dengue cases to date, and the vast majority of these cases were reported among people who contracted the illness while traveling abroad.
The CDC advised travelers to risk areas to prevent mosquito bites by
Dengue is a disease caused by a virus spread through mosquito bites. It is transmitted through infected mosquitoes, primarily the species Aedes aegypti.
The breakbone fever is caused by an infection with any of four different dengue viruses. These include:
Common Symptoms of the dengue are:
The disease can take up to 2 weeks to develop, with illness generally lasting less than a week.
However, it can quickly become severe within a few hours, usually requiring hospitalization.
In severe cases, health effects can include hemorrhage (uncontrolled bleeding), shock (seriously low blood pressure), organ failure, and death.
According to the World Health Organization (WHO), about half of the world's population is now at risk of dengue.
It estimates that:
The two main authorized vaccines in the world against dengue are Dengvaxia and Qdenga.
These vaccines are designed to protect against all four serotypes of the virus, with a focus on reducing severe disease and hospitalizations.
In addition, the Butantan-DV vaccine developed by the Butantan Institute in São Paulo has shown potential to be over 80 percent effective in preventing the risk of severe disease for up to five years. It also offers broader protection against all four dengue serotypes.
Credit: SoniaGandhi/X
Sonia Gandhi, Congress Parliamentary Party chairperson, is under treatment for systemic infection, said the doctors treating her at the private hospital in Delhi, today.
The Rajya Sabha MP was admitted to the Sir Ganga Ram Hospital on March 24, 2026. As per initial reports, she was feeling unwell due to the change in weather and has been put under observation.
"Sonia Gandhi has been admitted to Sir Ganga Ram Hospital on 24th March night for fever. As per Dr. Ajay Swaroop, Chairman of SGRH, she is undergoing treatment with antibiotics for systemic infection,” the hospital said in a statement.
She "is showing response to treatment", it added.
Earlier, the hospital noted that the doctors are conducting further investigations to check for possible infection in the stomach and urinary tract.
Systemic infection occurs in the bloodstream and affects the entire body, rather than a single organ or body part.
It occurs when pathogens like bacteria, viruses, or fungi enter the bloodstream and travel to multiple organs and tissues.
These infections can be life-threatening and common symptoms include:
Earlier this year, in January, Sonia Gandhi was admitted to Sir Ganga Ram Hospital after she suffered respiratory discomfort.
Also Read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?
Due to an increase in population during the peak winter season in Delhi, the 79-year-old Parliamentarian had been regular with hospital visits and check-ups. Hospital source, while speaking to the news agency PTI, said that "it is a routine admission".
According to reports, she had complained of some respiratory discomfort. Once her medical examination was done, it was found that "her bronchial asthma had been mildly exacerbated", confirmed Dr. Swaroop.
A hospital source told PTI that this is due to the combined effects of cold weather and pollution.
As a precautionary measure, she was admitted to the hospital for further observation and treatment. The physicians who were treating her made a decision on her discharge based on her clinical progress.
On June 7, 2025, she was admitted to the Indira Gandhi Medical College and Hospital (IGMC) in Shimla for a routine medical check-up. She was also later discharged after her medical examination.
As per Naresh Chauhan, Principal Advisor (Media) to the Himachal Pradesh Chief Minister, she was brought in due to minor health concerns. However, he said that after being put under observation by doctors to assess her condition, she was stable.
Dr. Aman Chauhan, Deputy Medical Superintendent at IGMC, said, "Her blood pressure was slightly on the higher side, but there is nothing serious. No additional tests were conducted; only routine investigations were carried out. She was not given any special medical advice because everything was perfectly fine."
In the same month, on June 15, she was admitted to Sir Ganga Ram Hospital again under the Department of Surgical Gastroenterology for a stomach-related issue. Before that, she was again in the Delhi hospital on June 9 for a medical check-up.
© 2024 Bennett, Coleman & Company Limited